Peek behind the paper: costs, exacerbations and pneumonia after initiating combination tiotropium and olodaterol versus triple therapy for COPD

Written by The Evidence Base

In this feature, we peek behind the paper with lead study author Swetha Palli (Boehringer Ingelheim Pharmaceuticals, CT, USA) to discuss the comparative costs, exacerbations and pneumonia associated with combination tiotropium and olodaterol versus triple therapy for individuals with chronic obstructive pulmonary disease (COPD). Read Palli’s full research article in the Journal of Comparative Effectiveness Research, for free, now>> Please could you introduce yourself? I am a Product Director in the Health Economics and Outcomes Research Value Demonstration team at Boehringer Ingelheim Pharmaceuticals (CT, USA). As lead author for this study, I am thrilled to be discussing the importance of...

To view the full article, please register now for access

It's completely free